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Abstract
Introduction: Observational studies suggest HIV and human papillomavirus (HPV) infections may have multiple interactions.
We reviewed the strength of the evidence for the influence of HIV on HPV acquisition and clearance, and the influence of
HPV on HIV acquisition.
Methods: We performed meta-analytic systematic reviews of longitudinal studies of HPV incidence and clearance rate by HIV
status (review 1) and of HIV incidence by HPV status (review 2). We pooled relative risk (RR) estimates across studies using
random-effect models. I2 statistics and subgroup analyses were used to quantify heterogeneity across estimates and explore
the influence of participant and study characteristics including study quality. Publication bias was examined quantitatively with
funnel plots and subgroup analysis, as well as qualitatively.
Results and Discussion: In review 1, 37 publications (25 independent studies) were included in the meta-analysis. HPV inci-
dence (pooled RR = 1.55, 95% CI: 1.29 to 1.88; heterosexual males: pooled RR = 1.95, 95% CI: 1.62, 2.34; females: pooled
RR = 1.63, 95% CI: 1.26 to 2.11; men who have sex with men: pooled RR = 1.36, 95% CI: 1.01 to 1.82) and high-risk HPV
incidence (pooled RR = 2.20, 95% CI: 1.90 to 2.54) was approximately doubled among people living with HIV (PLHIV) whereas
HPV clearance rate (pooled RR = 0.53, 95% CI: 0.42 to 0.67) was approximately halved. In review 2, 14 publications (11 inde-
pendent studies) were included in the meta-analysis. HIV incidence was almost doubled (pooled RR = 1.91, 95% CI 1.38 to
2.65) in the presence of prevalent HPV infection. There was more evidence of publication bias in review 2, and somewhat
greater risk of confounding in studies included in review 1. There was some evidence that adjustment for key confounders
strengthened the associations for review 2. Misclassification bias by HIV/HPV exposure status could also have biased esti-
mates toward the null.
Conclusions: These results provide evidence for synergistic HIV and HPV interactions of clinical and public health relevance.
HPV vaccination may directly benefit PLHIV, and help control both HPV and HIV at the population level in high prevalence
settings. Our estimates of association are useful for mathematical modelling. Although observational studies can never
perfectly control for residual confounding, the evidence presented here lends further support for the presence of biological
interactions between HIV and HPV that have a strong plausibility.
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1 | INTRODUCTION
The majority of individuals who are sexually active will acquire
human papillomavirus (HPV) infection at some point in their
lives, but most will develop the necessary immune response
and clear the infection [1,2]. However, in some individuals
infection is not cleared, and can progress to dysplasia, which
can eventually lead to carcinoma in situ, and invasive
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carcinoma. High-risk HPV types 16 and 18 account for about
70% of all cervical cancers and precancerous lesions, and a
substantial fraction of anal, vulvar, vaginal and penile cancers
[1,3]. The global burden of HPV-related disease is mainly con-
centrated in resource-poor settings where 85% of the esti-
mated 528,000 cervical cancer cases and 266,000 deaths
occurred in 2012 [1,4]. Sub-Saharan Africa faces a dual disease
burden as the region has some of the highest rates of cervical
cancer incidence and deaths, [4] and it accounts for approxi-
mately 70% of people living with HIV (PLHIV) worldwide [5,6].
HIV is believed to exacerbate the burden of cervical cancer.
Current evidence suggests that HIV and HPV infections
may interact in multiple ways [7]. Both viruses infect anogeni-
tal sites and are influenced by similar risk factors such as
number of sexual partners. However, there is also evidence
for direct biological and immunological interactions. Invasive
cervical carcinoma is an AIDS-defining illness due to increased
risk with immunosuppression [8,9] (although immunosuppres-
sion is not a necessary condition for HPV infection to pro-
gress to cancer). Similarly, HPV acquisition risk, persistence of
infection and disease progression to intraepithelial neoplasia
(such as cervical intraepithelial neoplasia (CIN) and anal
intraepithelial neoplasia (AIN)) and cancer may be increased
among people with a range of immunodeficiencies, including
as a consequence of HIV infection [2]. HIV interventions such
as medical male circumcision and anti-retroviral therapy (ART)
may directly and indirectly reduce the risk of HPV acquisition
and/or disease progression [10,11]. Previous systematic
reviews suggest that, similarly to other sexually transmitted
infections (STIs), HPV may in turn directly increase HIV sus-
ceptibility, either by breaching the epithelial barrier, recruiting
HIV target cells to the genital tract, or by generating a proin-
flammatory local immune milieu [12,13]. However, it is unclear
whether increased HIV acquisition depends on HPV type, the
number of HPV types present, and time since HPV infection,
that is, whether HPV infection is incident, prevalent, or
recently cleared, as a consequence of differences in the
immune response in each instance.
Quantifying the magnitude of the biological interactions
between HIV and HPV is important for many reasons. If HIV
and HPV biologically interact together by increasing suscepti-
bility to infection (for HIV and HPV), duration of infection (for
HPV), and the severity and risk of developing disease (for
HPV), it will facilitate HIV and HPV spread, and increase the
burden of HPV infection and diseases among PLHIV. Presence
of synergistic interactions would also mean that prevention
efforts against one infection could provide indirect population-
level benefits for the other. For example, if HPV vaccination
could prevent additional HIV infections and related deaths,
this could be particularly relevant for high HIV prevalence
countries in Sub-Saharan Africa and strengthen the case for
implementing HPV vaccination programmes in this region.
Estimating the size of these interactions is important to
parameterize mathematical models and understand how these
biological interactions and the rollout of HIV interventions
may influence future population-level trends in HPV and HIV
infections and related diseases, patterns of co-morbidity, and
HPV vaccination impact in high HIV prevalence settings.
Here, we present a systematic and meta-analytic review of
all the evidence for the association between HIV exposure
and subsequent risk of HPV acquisition and rate of HPV
clearance. For completeness, we also updated and re-analysed
two previous meta-analyses for the association between HPV
exposure and subsequent HIV acquisition, which had a latest
search date of 31st January 2012 [12,13]. In both of our
reviews, detailed assessments of the influence of study and
participant characteristics including study quality on pooled
estimates of the association, and the risk of confounding and
publication bias, are presented. These two reviews collectively
comprehensively assess the evidence for synergistic interac-
tions between the two infections.
2 | METHODS
The systematic reviews and meta-analyses were undertaken
in accordance with Meta-analysis of Observational Studies in
Epidemiology (MOOSE)[14] and Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)[15]
guidelines.
2.1 | Search strategy
PubMed and Embase databases were searched (up to 6th
January 2017) to identify longitudinal studies investigating the
association between HIV status and subsequent HPV acquisi-
tion and clearance (review 1) as well as the effect of HPV sta-
tus on subsequent HIV acquisition (review 2). We screened
publication titles, abstracts and articles for longitudinal studies
using a combination of keywords and MeSH terms relating to
HPV or cervical/anal/genital neoplasia, cancer, abnormalities
or lesions and HIV. Bibliographies of relevant articles were
examined for additional references. Details of the search
terms used are provided in Appendix S1.
2.2 | Study selection and data extraction
Publications were examined for eligibility to include prospec-
tive cohort studies, randomized controlled trials, and case–
control studies nested within a cohort or trial, where the time
sequence between HIV and HPV infections was determined,
that were published in the English language, and that mea-
sured active genital HPV infection by detection of the virus in
either cervical, penile or anal swabs or cervico-vaginal lavage
fluid using a test based on HPV DNA identification. We
excluded studies that only measured HPV antibodies, which
do not distinguish between current and past infection. No fur-
ther exclusions were made on the basis of study quality, which
was instead assessed in subgroup analyses and qualitatively.
The main associations of interest were the relative risk (RR)
of acquiring a new HPV infection or clearing an existing HPV
infection (outcomes) by HIV serostatus (exposure) (review 1),
and the RR of acquiring HIV infection (outcome) by HPV sta-
tus (either prevalent, recent/incident or recently cleared HPV
infection) (exposure) (review 2). Given the large number of
HPV types, we used the following standard HPV categories:
(any) HPV, high-risk HPV (HR-HPV), low-risk HPV (LR-HPV)
using the HPV groupings stated in the publications, and single
HPV types included in the nonavalent vaccine (HPV-6/11/16/
18/31/33/45/52/58). Where available, estimates for the asso-
ciation between HIV and number of HPV types (dose–re-
sponse for review 2), and estimates by CD4 cell count
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compared to HIV-negative individuals (dose–response for
review 1) were extracted. We did not include estimates which
only compared HPV risk between PLHIV by CD4 levels, with-
out using HIV negative as the comparator. Where possible,
and if not otherwise reported, we derived estimates with HIV-
negative individuals as the comparison group.
Studies measured HPV incidence and clearance in different
ways, which we defined as follows. For HPV incidence, two sit-
uations were possible. An individual’s HPV status could change
from (1) no HPV DNA present (but not necessarily na€ıve to
past HPV infection, that is, individuals could be seropositive to
a given type) to HPV DNA subsequently being present
(defined as “first HPV”); or from (2) DNA of one or more HPV
types present to DNA of a new and different HPV type
subsequently being present (defined as “new HPV”). For clear-
ance of HPV two situations were possible. An individual’s HPV
status could change from (1) DNA of one or more HPV types
present to no HPV DNA subsequently being present (defined
as “clearance of all HPV types”); or from (2) DNA of a specific
HPV type present to no DNA of that HPV type subsequently
being present (defined as “clearance of any HPV type”). In
addition, HPV clearance could be defined in the study on the
basis of one HPV negative test or two successive negative
tests.
The association between HIV and HPV for grouped HPV
types ([any]HPV, HR-HPV or LR-HPV) could be measured in
the study using one of three different units of analysis for
HPV: individual-level, type-level, or visit-level. At the individ-
ual-level, only one occurrence for each HPV event was
counted per individual during the entire follow-up period. This
meant that, for incident HR-HPV, for example, an individual
could acquire both HPV-16 and HPV-18 but this would only
count as one event. By definition, clearance of all HPV types
could only be measured at the individual-level. When mea-
sured at the type-level, an individual could have multiple
events occurring at different times, for example, acquire multi-
ple HPV types. The studies would count them and the rates
would then be averaged over the group of HPV types
(HR-HPV or LR-HPV) acquired. Note these units are equiva-
lent for the incidence (or alternatively clearance) of one HPV
type as only one event is possible. At the visit-level, which
was less commonly used as the unit of analysis across studies,
only one event could be counted per individual for each study
interval, but events were then summed for all study intervals
over the entire follow-up period.
Eligible studies were examined (KJL) to extract crude RR
and adjusted aRR estimates (by sex, where possible) and 95%
confidence intervals (95% CI), as well as information on partic-
ipant characteristics (e.g. geographical region, risk population)
and study characteristics (e.g. type of RR, study year), includ-
ing indicators of study quality such as frequency of visits/test-
ing interval and key variables adjusted for, in a standardised
form (comprehensive list in Table 1). A second reviewer
checked the data extraction and calculations (MMR). In order
of preference, for both reviews RR estimates based on hazard
or incidence rate ratio (HRR), cumulative risk ratio (CRR), or
odds ratio (OR) were extracted. If multiple estimates of the
same association and using the same RR measure were
reported by multiple publications reporting on the same study,
the estimate corresponding to the largest sample size was
extracted. If a publication (or multiple publications from the
same study) reported multiple relevant associations (such as
the association between HIV status and acquisition of first
HPV infection and the association between HIV status and
acquisition of new HPV infection), they were all extracted and
tabulated although only one independent estimate was
included in the pooled estimate of a specific association.
Where crude estimates or their 95% CI were not reported,
but sufficient information was provided, we calculated
(in order of preference) the crude HRR or CRR and 95% CI
(details in Appendix S1).
2.3 | Meta-analysis
For each association, forest plots and pooled estimates were
used to summarize independent RR estimates across studies.
Pooled natural log RR estimates and 95% CI of log trans-
formed study RR estimates were derived using a random-
effects model based on the inverse-variance method [16]. For
each association, one RR estimate per study for each sex was
included according to the following algorithm: we preferably
used estimates (1) based on the female sample, if female and
male estimates were non-independent (such as in couples
studies); (2) based on new HPV over first HPV, and on clear-
ance of all HPV types over clearance of any HPV type, if both
were reported in a study; (3) using individuals as unit of analy-
sis, if a study reported multiple estimates based on different
unit of analysis; and (4) based on penile samples over anal
samples, if both were reported in a study. The influence of (1),
(2), (3) and (4) was explored in subgroup analyses. For review
2, we also derived additional pooled estimates with alternative
comparison groups to HPV-negative (e.g. prevalent HR-HPV
vs. HR-HPV-negative) to compensate for the few available
estimates using HPV-negative as the comparison. Estimates
without 95% CI or which were numerically undefined (e.g. due
to no unexposed cases) were excluded from the meta-analysis.
Statistical heterogeneity across study estimates was assessed
with the I2 statistic. Subgroup analyses were used to explore
the influence of participant and study characteristics and qual-
ity for the associations with HPV and HR-HPV. The meta-ana-
lyses were done in Stata (version 14) and forest plots
produced in R.
2.4 | Study quality and publication bias
Information on study quality from the data extraction, such as
definitions of HPV incidence and clearance and unit of analy-
sis, was assessed quantitatively using subgroup analyses by
relevant study characteristics. In particular, we assessed
potential for confounding, for example, in adjusted estimates
using subgroup analysis by whether or not a key confounder
(HSV-2, number of sexual partners, hormonal contraception,
male circumcision, condom use) was adjusted for. We also
compared pooled crude and adjusted estimates for the subset
of studies which reported both types of estimates. Publication
bias was assessed in three ways: first with funnel plots of
crude study estimates as described in Appendix S1, and sec-
ond with subgroup analysis comparing pooled crude RR from
estimates directly reported in publications with estimates not
reported but which were derived from available information.
This assumes that in the presence of publication bias, the lat-
ter would be smaller than estimates directly reported in
Looker KJ et al. Journal of the International AIDS Society 2018, 21:e25110
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25110/full | https://doi.org/10.1002/jia2.25110
3
Table 1. Summary of characteristics of the 37 independent studies included.
Characteristic
Number of independent studies (N = 37)
Review 1: Effect of HIV on HPV acquisition
and clearance (N = 27 independent studies)
Review 2: Effect of prevalent or
incident HPV or HPV clearance
on HIV acquisition
(N = 11 independent studies)
Sex Males 7 [17,18,36,37,50,52-54,70] 4 [12,55-57,64,65]
Females 18 [19,21-35,38,39,41-47,49,51,67,68] 7 [12,43,58-63,66,69]
Both males and females 2 [20,40,48] 0
Region North America 10 [17-35,47-49] 1 [55]
South America 3 [36,51,68] 0
Europe 4 [37-39,70] 0
Sub-Saharan Africa 9 [40-46,50,54,67] 10 [12,43,56-66,69]
Asia and Pacific 1 [52,53] 0
Risk population General population
(including couples studies)
7 [40,41,43,44,50,54,67,68] 6 [12,43,56, 57,59-61,64-66]
ANC/pregnant 3 [42,46,51] 0
MSM 5 [17,18,37,52,53,70] 1 [55]
PWID 2 [19,24,25] 0
Gynaecology clinic 1 [38] 0
Other higher risk populations 9 [20-23,26-36,39,45,47-49] 4 [12,58,62,63,69]
Study year (midpoint) <1989-1996 9 [17,18,24-35,45,46,49] 0
1997-2006 10 [20-23,36-39,41-44,47,48] 10 [12,43,55-57,59-66,69]
≥2007 5 [51-53,67,68,70] 1 [58]
Not reported 3 [19,40,50,54] 0
Study design Individual-based studies 26 [17-39,41-54,67,68,70] 11 [12,43,55-66,69]
Couple-based studies 1 [40] 0
Study type Longitudinal (cohort or trial) 27 [17-54,67,68,70] 8 [12,55-64]
Case–control with
a time element
0 3 [12,43,65,66,69]
Follow-up duration Range 6 to 53 months [17-33,35-54,67,68,70] 12 to 48 months [12,43,55-66,69]
Unspecified 1 [34] 0
Length of time
between visits
≤6 months 17 [18,19,21-38,40,42,43,47,49,51,67,70] 6 [12,43,55,58,59,62,66,69]
>6 months 3 [20,44,46,48] 0
Not regularly spaced 4 [17,45,50,52-54] 4 [12,56,57,60,61,64,65]
Not reported 3 [39,41,68] 1 [63]
HPV infectiona HPV 13 [17-20,24-30,38-42,46,48,49,68] 9 [12,43,56-62,64-66,69]
HR-HPV 10 [19-23,31-33,35,40,44,47,48,50,52-54,70] 9 [12,43,56-61,63-66,69]
LR-HPV 2 [31-33,40] 8 [12,43,56-59,63-66,69]
Single HPV vaccine types 8 [21-23, 26-33,37,44,47,49,50,52-4,70] 1 [12,59]
Number of HPV types 2 [43,50,54] 6 [12, 43, 55–57, 63–66]
Definition of incident
HPV infection
(for grouped type)
First 13 [17-23,26-30,38-41,46-49,68,70] 3 [12,60,61,65,69]
New 10 [17,24-33,35,40,42,44,49,52-54] 1 [12,43,66]
HPV clearanceb HPV 15 [17,18,20,24-30,34,36,38-42,45,46,48,49,51] 3 [12,43,65,66,69]
HR-HPV 10 [21-23,26-35,44,45,47,49,50,52-54,67,70] 2 [12,59-61]
LR-HPV 3 [31-34,45] 1 [59]
Single HPV vaccine types 8 [21-25,31-33,44,45,47,50,52-54,70] 0
Number of HPV types 0 1 [65]
Definition of HPV
clearance
(for grouped type)
All types 17 [17,18,20-30, 34-36,38,39,41,45-49,51-53,67] 2 [12, 59–61]
Any 8 [26-33,40,42,49,50,52-54,67,70] 3 [12,43,65,66,69]
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publications. Third, during the data extraction we identified sit-
uations where an association had been investigated, but
where results were selectively reported, for example, accord-
ing to statistical significance. This information was then evalu-
ated qualitatively.
3 | RESULTS AND DISCUSSION
3.1 | Study selection
Of the 6430 potential publications identified from the
PubMed and Embase searches, 55[12,17-70] met our inclu-
sion criteria. Figure 1 summarizes publication selection,
Table 1 summarizes the characteristics of the included stud-
ies, and Tables S1,S2,S3,S4 (Appendix S1) describe the
extracted data and their quality. In review 1, of the effect of
HIV status (exposure) on subsequent HPV acquisition and
clearance (outcomes), we extracted data from a total of 41
publications reporting on 27 independent studies [17-54]. In
review 2, of the effect of HPV status (exposure) on subse-
quent HIV acquisition (outcome), we extracted data from a
total of 15 publications reporting results from 11 independent
studies [12,43,55-66]. This included one published review that
provided additional unpublished estimates from other studies
[12]. One publication [43] was included in both reviews. Four
of the 55 publications included did not report RR and/or 95%
CI estimates or sufficient data to derive them, or had impre-
cise information on the time sequence of infection, and could
not be included in the meta-analysis [22,29,37,60]. The publi-
cation [43] from which data were extracted for both reviews
did not present any data for our main associations of interest
for review 1 and was therefore not included in any meta-ana-
lysis for review 1. This left 37 publications (25 independent
studies) for review 1 and 14 publications (11 independent
studies) for review 2 in the meta-analyses. Two studies in
review 2 were new additions to the previously published
meta-analyses [12,13].
3.2 | Study and participant characteristics
In review 1, 10 of the 27 studies were conducted in North
America and 9 in Sub-Saharan Africa (Table 1). Eighteen were
conducted among females only, and 9 were carried out before
1997 and 5 after 2006. Ten studies were conducted among
lower risk populations (participants who were recruited from
the general population and antenatal clinic attendees), while
Table 1. (Continued)
Characteristic
Number of independent studies (N = 37)
Review 1: Effect of HIV on HPV acquisition
and clearance (N = 27 independent studies)
Review 2: Effect of prevalent or
incident HPV or HPV clearance
on HIV acquisition
(N = 11 independent studies)
Unit of analysis Individual-level 25 [17-49,51-53,67,68] 11 [12,43,55-64,66,69]
Type-level 5 [26-30,40,44,49,50,54,70] 1 [59]
Visit-level 2 [24,25,50,54] 1 [65]
Measure of
association
HRR 15 [17,19-33,35,37,40,44,45,47-50,52-54,70] 8 [12,43,55-57,59-64,66]
CRR 16 [17,18,21-30,34,36,38,39,41,42,46,47,
49-51,54,67,68]
6 [12,43,57,58,63-66,69]
OR 5 [21-30,42,43,47,49] 3 [12,43,65,66,69]
Crude 26 [17-40,42-54,67,68, 70] 11 [12,43,55-66,69]
Adjusted 16 [17,19-30,40-45,47-54,70] 10 [12,43,55-57,59-66,69]
Stratified by
CD4 level
Cutpoints varied
across studies
8 [17, 21-23,26-30,34,35,40,47,49,70] Not applicable
Key variables
adjusted for
HSV-2 3 [19,20,26-30,48,49] 8 [12,43,55-57,59,62, 64-66,69]
No. of sexual partners 12 [17,19,20,24-30,41,43-45,48-50,52-54,70] 6 [12,43,55,56,60,61,63,65,66]
Hormonal contraception 2 [20,45,48] 2 [12,43,60, 61,66]
Male circumcision 2 [50,54,70] 4 [12, 56, 57, 59, 64, 65]
Condom use 5 [17,19,20,45,48,52,53] 8 [12,43,55-57,59-61,63-66]
ANC, Antenatal clinic attendees; MSM, men who have sex with men; PWID, people who inject drugs; HRR, hazard rate ratio; CRR, cumulative risk
ratio; OR, odds ratio.
aDefined for incident HPV as first (among those with no HPV DNA present at baseline but not necessarily na€ıve to past HPV infection) or new
(among individuals who are already had HPV DNA of another type at baseline) HPV group type not present at baseline.
bDefined as clearance of all HPV types or clearance of any one type or an average of type-specific clearance rates. The unit of analysis was
entered as “individual-level” for the association between HIV and acquisition/clearance for single HPV types as this is equivalent to “type-level”
being the unit of infection for single HPV types, unless “type-level” was the unit of analysis for other estimates. Studies are counted more than
once where they presented estimates for more than one association, unit of analysis or measure of association, or adjusted for more than one
confounding factor. Measure of association refers to the measure entered in Tables S1 and S2. One study was counted in both reviews.
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the remaining 17 studies were among higher risk populations
(e.g. studies which included men who have sex with men
(MSM), people who inject drugs (PWID) and female sex work-
ers (FSW)).
In review 1, studies reported on the association between
HIV and incident HPV infection for infection with HPV
(N = 13), HR-HPV (N = 10), LR-HPV (N = 2), single HPV non-
avalent vaccine type (N = 8) and by number of HPV types
acquired (N = 2). Studies reported RR estimates of HPV clear-
ance by HIV status for HPV (N = 15), HR-HPV (N = 10), LR-
HPV (N = 3) and single HPV nonavalent vaccine type (N = 8).
Eight studies compared HPV incidence or HPV clearance out-
comes between HIV-negative and PLHIV stratified by CD4
level (dose–response), six of which reported results of a statis-
tical test for trend by CD4 level (Table S1; see Appendix S1).
In review 2, 10 of the 11 studies were conducted in Sub-
Saharan Africa (one study was from North America), all after
1996 with 1 after 2006, and 7 among females (Table 1). Par-
ticipants were recruited from general (N = 6) and higher risk
populations (N = 4) and one from MSM. Studies reported RR
estimates for the association between incident HIV and pre-
ceding exposure to prevalent HPV (N = 9), prevalent HR-HPV
(N = 9), prevalent LR-HPV (N = 8), single HPV nonavalent
vaccine type (N = 1), and by number of HPV types present
(dose–response) (N = 6). Few studies reported RR estimates
of incident HIV following HPV incidence for first HPV (N = 3)
and for new HPV (N = 1), and following HPV clearance for
HPV irrespective of type (N = 3), for HR-HPV (N = 2), and by
number of HPV types (dose–response) (N = 1).
3.3 | Meta-analysis results for review 1
3.3.1 | HPV acquisition by HIV status
Both the pooled crude RR and adjusted aRR suggested a sta-
tistically significant increased risk of acquisition of HPV
(pooled RR = 1.55, 95% CI: 1.29 to 1.88; pooled aRR = 2.46,
95% CI: 1.86 to 3.26), HR-HPV (pooled RR = 2.20, 95% CI:
1.90 to 2.54; pooled aRR = 1.87, 95% CI: 1.32 to 2.67) and
HPV-16 (pooled RR 2.10, 95% CI: 1.63 to 2.67; pooled
aRR = 2.06, 95% CI: 1.04 to 4.08), and slightly more equivocal
increased risk of HPV-18 (pooled RR = 1.89, 95% CI: 1.32 to
2.70; pooled aRR = 1.88, 95% CI: 0.77 to 4.60), in PLHIV
compared to HIV-negative individuals (Figure 2a,b,c). Incident
HPV-31, HPV-33, HPV-45, HPV-52 and HPV-58 (range of
pooled RR: 1.88-2.79) were also positively and statistically sig-
nificantly associated with HIV status in crude pooled RR. The
only adjusted estimates (N = 1) were statistically significant
for HPV-45 and HPV-58 (Figure 2d). Incident LR-HPV was
positively and statistically significantly associated with HIV sta-
tus in crude pooled RR (pooled RR = 2.62, 95% CI: 2.04 to
3.36, N = 2); no adjusted estimates were available (Fig-
ure S1a,b; see Appendix S1). Pooled adjusted aRR tended to
have wider confidence intervals than RR because adjusted
estimates were less common. Statistical heterogeneity across
crude and adjusted study estimates for each HPV outcome
varied from 0% to 55%.
In subgroup analyses by participant and study characteris-
tics, the magnitude of the stratified pooled crude RR and
Figure 1. Results and selection of publications from the literature search.
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Figure 2. Forest plots for the crude and adjusted relative risk (RR) of: (a) incident HPV infection; (b) incident HR-HPV infection; (c) incident HPV-
16/HPV-18 infection; and (d) incident HPV-31/HPV-33/HPV-45/HPV-52/HPV-58 infection, by HIV status. In this plot all HIV infection is preva-
lent, and the comparison group (unexposed group) is those HIV-negative. An effect estimate greater than 1 indicates increased HPV incidence in
those with HIV infection compared to HIV-negative individuals. An asterisk next to the effect estimate indicates that this estimate was calculated
using data presented in the publication. NA, North America; EU, Europe; SSA, Sub-Saharan Africa; SA, South America; APAC, Asia and Pacific.
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Table 2. Subgroup analyses of the association between HIV exposure status and subsequent HPV infection by participant and
study characteristics (review 1). Pooled crude RR and adjusted aRR are presented for the following HPV outcomes: (a) incident
HPV; (b) incident HR-HPV; (c) clearance of HPV; (d) clearance of HR-HPV. Estimates in bold are statistically significantly different
to 1 (p < 0.05).
Study and participant characteristics
Crude pooled Adjusted pooled
N RR (95% CI) I2 (%) p valuef (X2) N aRR (95% CI) I2 (%) p valuef (X2)
a. Incident HPV
Sex
Malesc 4 1.42 (1.10, 1.82) 0.0 0.959 2 1.95 (1.51, 2.52) 0.0 0.729
Females 10 1.63 (1.26, 2.11) 36.2 0.119 4 2.77 (2.05, 3.75) 0.0 0.515
Region
North America 7 1.67 (1.36, 2.05) 0.0 0.563 2 2.24 (1.24, 4.04) 33.9 0.219
South America 1 0.96 (0.51, 1.82) - - - - - -
Europe 2 3.30 (0.74, 14.74) 41.2 0.192 - - - -
Sub-Saharan Africa 3 1.38 (0.94, 2.02) 46.4 0.155 3 2.68 (1.92, 3.75) 2.5 0.359
Economyd
Low- and middle-income economies 4 1.29 (0.93, 1.78) 36.2 0.195 3 2.68 (1.92, 3.75) 0.0 0.359
High-income economies 9 1.70 (1.39, 2.09) 0.0 0.483 2 2.24 (1.24, 4.04) 33.9 0.219
Risk populatione
MSM only (any site) 2 1.36 (1.01, 1.82) 0.0 0.912 1 1.80 (1.07, 3.02) - -
MSM, penile samples alone - - - - - - - -
MSM, anal samples alone 1 1.35 (0.99, 1.84) - - 1 1.80 (1.07, 3.02) - -
Heterosexual men only 2 1.95 (1.62, 2.34) 0.0 0.734 1 2.00 (1.49, 2.53) - -
Higher risk populations 9 1.70 (1.39, 2.09) 0.0 0.483 2 2.24 (1.24, 4.04) 33.9 0.219
Lower risk populations 4 1.29 (0.93, 1.78) 36.2 0.195 3 2.68 (1.92, 3.75) 2.5 0.359
Study year (midpoint)
<1997 5 1.40 (1.12, 1.75) 0.0 0.467 1 1.80 (1.07, 3.02) - -
1997 to 2006 6 1.82 (1.29, 2.56) 24.2 0.252 3 2.37 (1.39, 4.06) 0.0 0.404
≥2007 2 1.45 (0.68, 3.10) - - 1 2.98 (2.07, 4.29) - -
Incidence definition
First incident HPV infectiona 11 1.56 (1.25, 1.94) 20.1 0.252 3 2.21 (1.46, 3.34) 0.0 0.424
New incident HPV infectionb 4 1.80 (1.13, 2.87) 85.4 <0.001 3 2.49 (1.86, 3.34) 15.9 0.304
Measure of association
ALL 13 1.55 (1.29, 1.88) 19.9 0.243 5 2.46 (1.86, 3.26) 6.7 0.369
HRR 4 2.11 (1.56, 2.86) 0.0 0.932 3 2.57 (1.79, 3.69) 29.5 0.242
CRR 9 1.36 (1.11, 1.66) 6.6 0.380 1 2.80 (0.92, 8.50) - -
OR - - - - 1 1.50 (0.63, 3.57) - -
Unit of analysis
Individual-level 13 1.55 (1.29, 1.88) 19.9 0.243 4 2.06 (1.42, 2.99) 0.0 0.505
Type-level - - - - 1 2.98 (2.07, 4.29) - -
Key variables adjusted for
HSV-2
Yes - - - - 1 3.40 (1.42, 8.13) - -
No - - - - 4 2.33 (1.67, 3.24) 19.8 0.291
Number of sexual partners
Yes - - - - 3 2.21 (1.46, 3.34) 0.0 0.424
No - - - - 2 2.38 (1.26, 4.57) 51.1 0.153
Hormonal contraception
Yes - - - - - - - -
No - - - - 5 2.46 (1.86, 3.26) 6.7 0.369
Male circumcision
Yes - - - - - - - -
No - - - - 5 2.46 (1.86, 3.26) 6.7 0.369
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Table 2. (Continued)
Study and participant characteristics
Crude pooled Adjusted pooled
N RR (95% CI) I2 (%) p valuef (X2) N aRR (95% CI) I2 (%) p valuef (X2)
Condom use
Yes - - - - 2 2.24 (1.24, 4.04) 33.9 0.219
No - - - - 3 2.68 (1.92, 3.75) 2.5 0.359
Comparing subset with crude and adjusted 4 1.54 (1.16, 2.05) 31.8 0.221 4 2.38 (1.68, 3.38) 29.2 0.237
Risk of publication bias
Estimate reported in study 1 2.50 (1.13, 5.54) - - 5 2.46 (1.86, 3.26) 6.7 0.369
Estimate derived from study information 12 1.51 (1.25, 1.83) 18.2 0.321 - - - -
b. Incident HR-HPV
Sex
Males 4 1.90 (1.35, 2.67) 34.4 0.206 1 1.43 (0.99, 2.06) - -
Females 7 2.37 (1.97, 2.87) 0.0 0.718 2 2.18 (1.58, 3.01) 0.0 0.375
Region
North America 6 2.22 (1.74, 2.83) 0.0 0.784 1 3.00 (1.38, 6.51) - -
Europe 1 1.42 (1.04, 1.93) - - 1 1.43 (0.99, 2.06) - -
Sub-Saharan Africa 3 2.40 (2.11, 2.74) 0.0 0.630 1 2.04 (1.43, 2.91) - -
Asia and Pacific 1 2.30 (1.24, 4.26) - - - - - -
Economyd
Low- and middle-income economies 4 2.40 (2.10, 2.73) 0.0 0.815 1 2.04 (1.43, 2.91) - -
High-income economies 7 1.95 (1.55, 2.45) 18.8 0.286 2 1.91 (0.94, 3.87) - -
Risk populatione
MSM only (any site) 2 1.67 (1.07, 2.62) 46.8 0.170 1 1.43 (0.99, 2.06) - -
MSM, penile samples alone 1 1.42 (1.04, 1.93) - - 1 1.43 (0.99, 2.06) - -
MSM, anal samples aloneg 2 1.82 (1.47, 2.25) 0.0 0.424 1 1.63 (1.29, 2.06) - -
Heterosexual men only 2 2.49 (1.54, 4.04) 0.0 0.976 - - - -
Higher risk populations 7 1.82 (1.50, 2.21) 0.3 0.421 2 1.91 (0.94, 3.87) 65.2 0.090
Lower risk populations 4 2.42 (2.13, 2.75) 0.0 0.791 1 2.04 (1.43, 2.91) - -
Study year (midpoint)
<1997 2 2.10 (1.47, 2.99) 24.3 0.251 - - - -
1997 to 2006 5 2.50 (1.94, 3.23) 0.0 0.970 2 2.18 (1.58, 3.01) 0.0 0.375
≥2007 4 2.12 (1.53, 2.95) 69.5 0.020 1 1.43 (0.99, 2.06) - -
Incidence definition
First incident HPV infectiona 6 2.19 (1.55, 3.10) 41.0 0.132 2 1.91 (0.94, 3.87) 65.2 0.090
New incident HPV infectionb 5 2.32 (2.05, 2.61) 0.0 0.721 1 2.48 (1.79, 3.43) - -
Measure of association
ALL 11 2.20 (1.90, 2.54) 22.0 0. 234 3 1.87 (1.32, 2.67) 45.6 0.159
HRR 11 2.20 (1.90, 2.54) 22.0 0. 234 3 1.87 (1.32, 2.67) 45.6 0.159
Unit of analysis
Individual-level 9 2.37 (1.98, 2.83) 0.0 0.883 2 2.18 (1.58, 3.01) 0.0 0.375
Type-level 2 1.86 (1.14, 3.05) 88.0 0.004 1 1.43 (0.99, 2.06) - -
Key variables adjusted for
HSV-2
Yes - - - - 1 3.00 (1.38, 6.51) - -
No - - - - 2 1.71 (1.21, 2.43) 46.7 0.171
Number of sexual partners
Yes - - - - 3 1.87 (1.32, 2.67) 45.6 0.159
No - - - - - - - -
Hormonal contraception
Yes - - - - - - - -
No - - - - 3 1.87 (1.32, 2.67) 45.6 0.159
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Table 2. (Continued)
Study and participant characteristics
Crude pooled Adjusted pooled
N RR (95% CI) I2 (%) p valuef (X2) N aRR (95% CI) I2 (%) p valuef (X2)
Male circumcision
Yes - - - - 1 1.43 (0.99, 2.06) - -
No - - - - 2 2.18 (1.58, 3.01) 0.0 0.375
Condom use
Yes - - - - 1 3.00 (1.38, 6.51) - -
No - - - - 2 1.71 (1.21, 2.43) 46.7 0.171
Comparing subset with crude and adjusted 3 2.10 (1.31, 3.37) 74.2 0.021 3 1.87 (1.32, 2.67) 45.6 0.159
Risk of publication bias
Estimate reported in study 6 2.09 (1.69, 2.59) 54.0 0.054 2 2.18 (1.58, 3.01) 0.0 0.375
Estimate derived from study information 5 2.60 (1.93, 3.49) 0.0 0.950 - - - -
c. Clearance of HPV
Sex
Malesc 3 0.74 (0.62, 0.87) 0.0 0.800 2 0.54 (0.31, 0.95) 85.1 0.010
Females 10 0.52 (0.40, 0.68) 80.2 <0.001 7 0.52 (0.38, 0.71) 67.7 0.005
Region
North America 4 0.58 (0.47, 0.72) 28.4 0.242 3 0.54 (0.35, 0.82) 65.3 0.056
South America 2 0.89 (0.57, 1.41) 34.2 0.218 1 1.00 (0.59, 1.68) - -
Europe 2 0.38 (0.21, 0.68) 0.0 0.487 - - - -
Sub-Saharan Africa 4 0.45 (0.29, 0.69) 87.0 <0.001 4 0.40 (0.32, 0.51) 13.4 0.325
Economyd
Low- and middle-income economies 6 0.54 (0.36, 0.80) 87.0 <0.001 5 0.48 (0.32, 0.71) 70.2 0.009
High-income economies 6 0.55 (0.44, 0.69) 27.6 0.228 3 0.54 (0.35, 0.82) 65.3 0.056
Risk populatione
MSM only (any site) 1 0.62 (0.29, 1.32) - - 1 0.40 (0.28, 0.57) - -
MSM, penile samples alone - - - - - - - -
MSM, anal samples alone - - - - 1 0.40 (0.28, 0.57) - -
Heterosexual men only 2 0.74 (0.63, 0.88) 0.0 0.631 1 0.71 (0.55, 0.92) - -
Higher risk populations 8 0.48 (0.36, 0.64) 69.0 0.002 4 0.46 (0.31, 0.70) 74.7 0.008
Lower risk populations 4 0.62 (0.41, 0.94) 83.9 <0.001 4 0.55 (0.36, 0.84) 61.3 0.051
Study year (midpoint)
<1997 6 0.46 (0.32, 0.65) 78.7 <0.001 3 0.37 (0.29, 0.48) 1.7 0.362
1997 to 2006 4 0.59 (0.40, 0.87) 41.4 0.163 3 0.57 (0.38, 0.86) 38.3 0.198
≥2007 2 0.71 (0.35, 1.46) 91.5 0.001 2 0.66 (0.31, 1.41) 84.4 0.011
Clearance definition
Loss of detection of all HPV types 10 0.51 (0.38, 0.69) 77.2 <0.001 6 0.51 (0.34, 0.75) 75.0 0.001
Loss of detection of any HPV type 2 0.62 (0.41 0.94) 82.1 0.018 2 0.47 (0.36, 0.61) 0.0 0.794
Test definition of clearance
1 negative test 11 0.58 (0.48, 0.72) 61.9 0.003 6 0.51 (0.38, 0.67) 47.9 0.087
2 consecutive negative tests 1 0.30 (0.22, 0.41) - - 2 0.48 (0.21, 1.09) 90.6 0.001
Measure of association
ALL 12 0.53 (0.42, 0.67) 75.9 <0.001 8 0.50 (0.38, 0.66) 65.5 0.005
HRR 2 0.39 (0.24, 0.65) 85.9 0.008 4 0.45 (0.33, 0.63) 74.4 0.008
CRR 10 0.60 (0.48, 0.75) 60.1 0.007 2 0.60 (0.19, 1.92) 75.7 0.042
OR - - - - 2 0.51 (0.33, 0.79) 0.0 0.898
Unit of analysis
Individual-level 10 0.51 (0.38, 0.69) 77.2 <0.001 6 0.51 (0.34, 0.75) 75.0 0.001
Type-level 2 0.62 (0.41 0.94) 82.1 0.018 2 0.47 (0.36, 0.61) 0.0 0.794
Key variables adjusted for
HSV-2
Yes - - - - 2 0.68 (0.50, 0.92) 0.0 0.437
No - - - - 6 0.46 (0.34, 0.63) 64.0 0.016
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Table 2. (Continued)
Study and participant characteristics
Crude pooled Adjusted pooled
N RR (95% CI) I2 (%) p valuef (X2) N aRR (95% CI) I2 (%) p valuef (X2)
Number of sexual partners
Yes - - - - 5 0.45 (0.31, 0.65) 68.1 0.014
No - - - - 3 0.56 (0.37, 0.96) 69.4 0.038
Hormonal contraception
Yes - - - - 2 0.48 (0.21, 1.09) 90.6 0.001
No - - - - 6 0.51 (0.38, 0.67) 47.9 0.087
Male circumcision
Yes - - - - - - - -
No - - - - 8 0.50 (0.38, 0.66) 65.5 0.005
Condom use
Yes - - - - 3 0.45 (0.28, 0.74) 83.0 0.003
No - - - - 5 0.55 (0.39, 0.77) 48.4 0.101
Comparing subset with crude and adjusted 5 0.57 (0.37, 0.89) 88.5 <0.001 5 0.51 (0.35, 0.73) 68.6 0.012
d. Clearance of HR-HPV
Sex
Males 3 0.65 (0.34, 1.25) 93.5 0.000 3 0.52 (0.19, 1.42) 93.2 <0.001
Females 7 0.68 (0.61, 0.76) 13.8 0.324 1 0.71 (0.58, 0.91) - -
Region
North America 5 0.65 (0.53, 0.79) 39.8 0.156 - - - -
Europe 1 1.33 (1.02, 1.73) - - 1 1.28 (0.96, 1.71) - -
Sub-Saharan Africa 3 0.68 (0.61, 0.76) 0.0 0.876 2 0.58 (0.37, 0.92) 70.9 0.064
Asia and Pacific 1 0.24 (0.12, 0.49) - - 1 0.22 (0.11, 0.46) - -
Economyd
Low- and middle-income economies 4 0.64 (0.51, 0.80) 65.0 0.036 3 0.44 (0.24, 0.81) 81.8 0.004
High-income economies 6 0.74 (0.54, 1.00) 82.1 <0.001 1 1.28 (0.96, 1.71) - -
Risk populatione
MSM only (any site) 2 0.58 (0.11, 3.12) 95.0 <0.001 2 0.55 (0.10, 3.08) 94.9 <0.001
MSM, penile samples alone 1 1.33 (1.02, 1.73) - - 1 1.28 (0.96, 1.71) - -
MSM, anal samples aloneg 2 0.43 (0.16, 1. 15) 86.8 0.006 2 0.42 (0.13, 1.34) 89.4 0.002
Heterosexual men only 1 0.67 (0.59, 0.76) - - 1 0.44 (0.28, 0.69) - -
Higher risk populations 6 0.63 (0.43, 0.91) 86.7 <0.001 2 0.55 (0.10, 3.08) 94.9 <0.001
Lower risk populations 4 0.69 (0.62, 0.76) 0.0 0.844 2 0.58 (0.37, 0.92) 70.9 0.064
Study year (midpoint)
<1997 3 0.69 (0.59, 0.81) 14.3 0.311 - - - -
1997 to 2006 3 0.59 (0.41, 0.85) 47.2 0.151 1 0.71 (0.58, 0.91) - -
≥2007 4 0.69 (0.45, 1.06) 90.3 <0.001 3 0.52 (0.19, 1.42) 93.2 <0.001
Clearance definition
Loss of detection of all HR-HPV types 6 0.60 (0.46, 0.79) 64.9 0.014 1 0.22 (0.11, 0.46) - -
Loss of detection of any HR-HPV type 4 0.78 (0.57, 1.05) 87.6 <0.001 3 0.75 (0.44, 1.30) 88.9 <0.001
Test definition of clearance
1 negative test 8 0.65 (0.56, 0.76) 51.1 0.046 3 0.44 (0.24, 0.81) 81.8 0.004
2 consecutive negative tests 2 0.89 (0.41, 1.94) 94.8 <0.001 1 1.28 (0.96, 1.71) - -
Measure of association
ALL 10 0.69 (0.57, 0.83) 77.0 <0.001 4 0.59 (0.33, 1.05) 90.0 <0.001
HRR 7 0.65 (0.49, 0.86) 84.6 <0.001 3 0.64 (0.32, 1.28) 91.3 <0.001
CRR 3 0.73 (0.63, 0.84) 0.0 0.985 1 0.44 (0.28, 0.69) - -
Unit of analysis
Individual-level 6 0.60 (0.46, 0.79) 64.9 0.014 2 0.33 (0.17, 0.65) 60.8 0.110
Type-level 4 0.78 (0.57, 1.05) 87.6 <0.001 2 0.95 (0.53, 1.69) 89.3 0.002
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adjusted aRR for incidence of HPV and HR-HPV by HIV sta-
tus were similar to unstratified pooled estimates (e.g. HIV on
HPV incidence among heterosexual males: pooled RR = 1.95,
95% CI: 1.62, 2.34, N = 2; females: pooled RR = 1.63, 95%
CI: 1.26 to 2.11, N = 10; MSM: pooled RR = 1.36, 95% CI:
1.01 to 1.82, N = 2), and remained statistically significant
overall, with the exception of pooled RR for subgroups based
on few study estimates, which were not always statistically
significantly different from the null (Table 2a,b).
3.3.2 | HPV clearance by HIV status
Both pooled crude RR and adjusted aRR suggested that the
clearance rate of HPV infection was approximately halved among
PLHIV compared to HIV-negative individuals (pooled RR = 0.53,
95% CI: 0.42 to 0.67; pooled aRR = 0.50, 95% CI: 0.38 to 0.66)
and similarly for HR-HPV (pooled RR = 0.69, 95% CI: 0.57 to
0.83; pooled aRR = 0.59, 95% CI: 0.33 to 1.05) (Figure 3a,b).
Associations between HIV and clearance of single type HPV had
wide confidence intervals, which were generally not statistically
significantly different from the null value (Figure 3c,d). The asso-
ciation between HIV status and LR-HPV was not statistically sig-
nificant (pooled RR = 0.77, 95% CI: 0.53 to 1.11, N = 2;
Figure S1c; see Appendix S1). Statistical heterogeneity across
HPV outcomes ranged from 0% to 90%.
In subgroup analyses, stratified pooled crude RR and
adjusted aRR for clearance of HPV and HR-HPV by HIV sta-
tus were similar in magnitude overall to unstratified pooled
estimates, and remained statistically significant, with the
exception of pooled RR for subgroups based on few estimates
only, which were not all statistically significantly different from
the null (Table 2c,d).
3.3.3 | Influence of CD4 cell count on HPV
acquisition and clearance
Figure 4 compares crude and adjusted study estimates of
the association between HIV and subsequent HPV incidence
and clearance for HPV and HR-HPV, by CD4 count,
compared to HIV-negative individuals. No results were
reported by CD4 count for LR-HPV. The pooled crude RR
for the association between HIV and incidence of HPV by
CD4 count was higher for CD4 level ≤200 cells/lL
(pooled RR = 6.65, 95% CI: 2.98 to 14.85; pooled
aRR = 5.76, 95% CI: 3.65 to 9.08) than CD4 level
>200 cells/lL (pooled RR = 3.20, 95% CI: 2.48 to 4.13;
pooled aRR = 3.09, 95% CI: 2.17 to 4.40), but not statisti-
cally significantly so (95% CI overlapped). Two of the four
available studies reported a test for trend and both showed
a statistically significant increase in HIV risk with declining
Table 2. (Continued)
Study and participant characteristics
Crude pooled Adjusted pooled
N RR (95% CI) I2 (%) p valuef (X2) N aRR (95% CI) I2 (%) p valuef (X2)
Key variables adjusted for
HSV-2
Yes - - - - - - - -
No - - - - 4 0.59 (0.33, 1.05) 90.0 <0.001
Number of sexual partners
Yes - - - - 4 0.59 (0.33, 1.05) 90.0 <0.001
No - - - - - - - -
Hormonal contraception
Yes - - - - - - - -
No - - - - 4 0.59 (0.33, 1.05) 90.0 <0.001
Male circumcision
Yes - - - - 2 0.76 (0.27, 2.2) 93.6 <0.001
No - - - - 2 0.42 (0.12, 1.31) 88.9 0.003
Condom use
Yes - - - - 1 0.22 (0.11, 0.46) - -
No - - - - 3 0.75 (0.44, 1.30) 88.9 <0.001
Comparing subset with crude and adjusted 3 0.66 (0.32, 1.34) 92.1 <0.001 3 0.64 (0.32, 1.28) 91.3 <0.001
aDefined as the subsequent detection of HPV DNA in those with no HPV DNA present at baseline but not necessarily na€ıve to past HPV
infection.
bDefined as the subsequent detection of HPV DNA among individuals who already had HPV DNA of another type present at baseline.
cMale category includes an estimate from Mbulawa (2012), which cannot be included in the main analyses as the estimate comes from a couples
study and male estimate is not independent from female estimate (included in the main analysis as per protocol).
dWorld Bank definition.
eMSM only: studies which only included men who have sex with men; Higher risk populations: studies which included female sex workers (FSWs),
men who have sex with men (MSM), people who inject drugs (PWID) or STI clinic attendees, or studies consisting of participants reporting higher
risk sex practices; Lower risk populations are participants from couples studies, antenatal care (ANC) clinics, or other general population samples.
fRelates to I2.
gEstimate from Mooij (2016) for anal sampling added in; estimate for penile sampling already included in main analysis as per protocol.
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Figure 3. Forest plots for the crude and adjusted relative risk (RR) of: (a) clearance of HPV; (b) clearance of HR-HPV; (c) clearance of HPV-16/
HPV-18; and (d) clearance of HPV-31/HPV-33/HPV-45/HPV-52/HPV-58, by HIV status. In this plot all HIV infection is prevalent, and the com-
parison group (unexposed group) is those HIV-negative. An effect estimate <1 indicates decreased rate of HPV clearance in those with HIV
infection compared to HIV-negative individuals. An asterisk next to the effect estimate indicates that this estimate was calculated using data
presented in the publication. NA, North America; EU, Europe; SA, South America; SSA, Sub-Saharan Africa; APAC, Asia and Pacific.
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Figure 4. Forest plot for the crude and adjusted relative risk (RR) of HPV incidence and clearance among PLHIV by CD4 count level compared to
HIV-negative for: (a) incident HPV infection; (b) incident HR-HPV infection; (c) clearance of HPV; (d) clearance of HR-HPV. In this plot all HIV infec-
tion is prevalent, and the comparison group (unexposed group) is those HIV-negative. An effect estimate greater than 1 (incident HPV) indicates
increased HPV incidence in those with HIV infection compared to HIV-negative individuals. An effect estimate less than 1 (HPV clearance) indi-
cates decreased rate of HPV clearance in those with HIV infection compared to HIV-negative individuals. An asterisk next to the effect estimate
indicates that the estimate was derived from available information in the publication. For Watts (2005) the estimate refers to clearance of incident
HPV types. NA, North America; EU, Europe; SSA, Sub-Saharan Africa.
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CD4 level (p = 0.03, p < 0.01; Table S1; see Appendix S1)
[17,24].
No other associations comparing CD4 level ≤200 cells/lL
and CD4 level >200 cells/lL were found (Figure 4b,c,d). The
two studies providing estimates by CD4 count for incident
HR-HPV by HIV status (Figure 4b) also reported a test for
trend: one was not statistically significant [70], while the other
one was statistically significant (p = 0.04) but suggested that
incident HR-HPV infection risk declined with decreasing CD4
count [35] (Table S1). Pooled estimates from the five studies
that measured the effect of HIV on HPV clearance by CD4
count suggested that lower CD4 count reduced clearance of
HPV, but non-statistically significantly so (Figure 4c). Of the
two studies reporting a test of trend one was statistically sig-
nificant and the other was not (p = 0.2[17] and p = 0.001[34]
(Table S1). Type-specific estimates by CD4 count for HPV-16/
18/31/45 were reported by three studies and were not statis-
tically significant (Figure S2a,b; see Appendix S1) [23,25,70].
3.4 | Meta-analysis results for review 2
3.4.1 | HIV acquisition by HPV status
Forest plots of pooled estimates for the association between
HPV and subsequent HIV acquisition suggested an approxi-
mate doubling of HIV incidence among individuals infected
with prevalent HPV (pooled RR = 1.91, 95% CI: 1.38 to 2.65;
pooled aRR = 1.75, 95% CI: 1.23 to 2.49), prevalent HR-HPV
(pooled RR = 1.63, 95% CI: 1.26 to 2.09; pooled aRR = 1.72,
95% CI: 1.37 to 2.17), and prevalent LR-HPV (pooled
RR = 1.72, 95% CI: 1.51 to 2.58; pooled aRR = 1.55, 95% CI:
0.93 to 2.58) (Figure 5a,c,d). Although statistical heterogeneity
across study estimates varied from 0% to 71%, study esti-
mates were consistently above one. Only one study reported
estimates for single prevalent HR-HPV nonavalent vaccine
types with wide confidence intervals, none of which was sta-
tistically significant apart from HPV-58 (individual RR = 2.58,
95% CI: 1.34 to 5.00; individual aRR = 2.13, 95% CI: 1.09 to
4.15). The effect of incident HPV (pooled RR = 1.70, 95% CI:
1.32 to 2.18; pooled aRR = 1.64, 95% CI: 1.21 to 2.21) and
clearance of HPV (pooled RR = 2.07, 95% CI: 1.10 to 3.90;
pooled aRR = 2.14, 95% CI: 0.35 to 13.11) on subsequent
HIV acquisition was similar to that for prevalent HPV (Fig-
ure 5b,f).
In subgroup analysis, the magnitude of the pooled crude RR
and adjusted aRR were not greatly influenced by participant
and study characteristics (Table S5; Appendix S1). Again, the
only stratified pooled estimates that were not statistically sig-
nificantly different than the null typically included only one or
two studies.
The risk of HIV acquisition increased with the number of
HPV types (aRR = 1.22 for increase in [any] HPV and
aRR = 1.59 for HR-HPV) (Table 3). Pooled estimates using
slightly different comparison groups for HPV exposure status
suggested similar magnitude of association to those using
HPV-negative as the comparison (Table 3).
3.5 | Study quality and publication bias
In review 1, 13 studies reported on the association between
HIV and incident HPV infection for first HPV and 10 for new
HPV (Table 1). Clearance was defined either as the loss of
detection of any HPV type (N = 8) or of all HPV types
(N = 17). Of the few studies that conducted adjusted analysis
for key confounding variables, most adjusted for number of
sexual partners (N = 12) and fewer studies adjusted for
other key factors (HSV-2: N = 3; hormonal contraception:
N = 2; male circumcision: N = 2; condom use: N = 5). In
review 2, a larger fraction of studies reported adjusted esti-
mates (HSV-2: N = 8; number of sexual partners: N = 6; hor-
monal contraception: N = 2; male circumcision N = 4;
condom use: N = 8). In both reviews, most studies used indi-
viduals as the unit of analysis rather than using HPV type or
visit, and in most studies the frequency of study visits was
bi-annually or more often over follow-up period ranging
between 6 and 53 months.
In our quantitative assessment of study quality using sub-
group analyses, stratified pooled estimates (adjusted or unad-
justed) by definitions of HPV incidence and clearance and
unit of analysis were similar in magnitude to unstratified
pooled estimates, and the associations generally remained
statistically significant overall (Table 2 and Table S5;
Appendix S1). There was some evidence in review 2 that
adjustment for key confounders strengthened the associa-
tions (Table S5; Appendix S1). We did not find any particular
trend when comparing crude and adjusted estimates for the
subset of studies which reported both. Qualitatively, in both
reviews we found evidence that exposed and unexposed
groups were often different at baseline with respect to sex-
ual risk factors or else this information was not reported,
while for review 1, PLHIV had higher baseline HPV preva-
lence than HIV-negative individuals (Tables 3 and S4;
Appendix S1).
In review 1, there was little evidence of publication bias. In
funnel plots (Figures S3,S4,S5,S6; see Appendix S1) most esti-
mates fell within the expected 95% CI area. In subgroup
analysis, pooled crude RR derived from directly reported
study estimates were somewhat higher than those derived
from available data for HPV, but not statistically significantly
so (pooled RR = 2.50, 95% CI: 1.13 to 5.54 vs. 1.51, 95% CI:
1.25 to 1.83), and not for HR-HPV (pooled RR = 2.09, 95%
CI: 1.69 to 2.59 vs. 2.60, 95% CI: 1.93 to 3.49) (Table 2a,b).
Our qualitative assessment found some evidence of selective
reporting of estimates (Tables S1,S3; see Appendix S1), but
this was not observed consistently for any specific associa-
tion. There was some evidence of publication bias in review
2. Although crude estimates generally fell within the expected
95% CI bounds of the funnel plots, they tended to be asym-
metrically distributed towards more significant values
(demonstrated by Egger’s regression line) (Figures S7,S8; see
Appendix S1). In subgroup analysis, pooled crude RR for HIV
incidence following exposure to prevalent HPV based on esti-
mates directly reported in the study were higher than those
derived from available data (pooled RR: 2.34, 95% CI: 1.51
to 3.62 vs. 1.42, 95% CI: 0.96 to 2.11), but not statistically
significantly so (95% CI overlapped) (Table S5a;
Appendix S1). The same was true for HR-HPV (pooled RR:
1.77, 95% CI: 1.38 to 2.27 vs. 1.57, 95% CI: 0.93 to 2.65)
(Table S5c; Appendix S1). Our qualitative assessment found
evidence of selective reporting of estimates for LR-HPV,
dose–response results and non-significant results (Tables S2,
S4; see Appendix S1).
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Figure 5. Forest plots of the crude and adjusted relative risk (RR) of HIV acquisition for: (a) prevalent HPV infection; (b) incident HPV infec-
tion; (c) prevalent HR-HPV infection; (d) prevalent LR-HPV infection; (e) HPV-16/HPV-18/HPV-31/HPV-33/HPV-52/HPV-58 infection; (f)
clearance of HPV. In this plot HPV infection is the exposure and HIV acquisition is the outcome. An asterisk next to the effect estimate
indicates that this estimate was calculated using data presented in the publication. SSA, Sub-Saharan Africa.
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3.6 | Summary of results
Our results indicate that the risk of subsequent HPV acquisi-
tion is approximately doubled in the presence of HIV infection,
while the rate of HPV clearance is approximately halved. We
updated previous meta-analyses of the effect of HPV on sub-
sequent HIV infection adding two new studies to earlier pub-
lished reviews [12,13]. Consistent with previous pooled
estimates, we observed a nearly doubling of HIV acquisition in
those individuals with HPV infection [12,13]. In both of our
reviews the magnitude of the associations was similar for LR-
HPV, HR-HPV and timing of HPV infection (incident, prevalent
or cleared infection), and was not influenced by any particular
participant or study characteristics, including study quality
indicators. There were some indications from the few studies
available that HPV acquisition and persistence increased as
CD4 level declined (review 1). There was also some evidence
of a dose–response between number of HPV types and HIV
acquisition risk (review 2), which may reflect increased biologi-
cal HIV susceptibility with increasing number of HPV infec-
tions, though could also be a marker of shared risk behaviour
[71] or some immunological susceptibility.
3.7 | Strengths and limitations
To the best of our knowledge, this is the first meta-analytic
review investigating all the evidence for the association
between HIV and subsequent HPV infection (review 1), not
just in women [72] (published after our review was carried
out). Our review adds further studies to those found in earlier
reviews of HIV-HPV infection interactions [12,13,72]. Our
review strengthens the evidence that HIV increases disease
burden among PLHIV not only by accelerating HPV disease
progression, but also by increasing HPV acquisition risk and
persistence [72-74]. Our two reviews collectively assessed the
strength of the evidence for synergistic interactions between
HIV and HPV infections. We explored in detail the influence
of participant and study characteristics including study quality
on pooled estimates, and explored possible publication and
measurement biases. Results were consistent in subgroup
analyses, by exposure and outcome definitions, between crude
and adjusted estimates, and across alternative comparison
groups.
As with other systematic and meta-analytic reviews of longi-
tudinal studies of STI and HIV interactions, there are some
limitations to our reviews that may affect our results in either
direction [12,13,72,75]. HPV and HIV are both STIs associated
with similar sexual risk factors, which may lead to overestima-
tion of the magnitude of STI and HIV associations. In our
review, study-level adjustment for key confounders, such as
number of sexual partners, condom use and HSV-2 was more
frequent for studies included in review 2 than review 1.
Recent modelling analyses of HPV and HIV, and of HSV-2 and
HIV, have suggested that observed associations could be
explained by confounding by sexual risk factors, in the absence
of biological interaction [76,77]. However, these effects are
likely to be greater for cross-sectional studies whereas our
review was based on longitudinal studies [78,79]. Further-
more, we found some evidence in review 2 that adjustment
for key confounding variables including sexual behaviour actu-
ally strengthened the associations. That said, even with
adjusted estimates the presence of residual confounding
Table 3. Further pooled estimates for dose–response and for additional exposures for the effect of HPV infection on HIV
acquisition (review 2).
Exposure
Crude pooled Adjusted pooled
RR (95% CI) N I2 (p value) aRR (95% CI) N I2 (p value)
a. Dose–response
1 prevalent HPV type (vs. HPV-negative) 1.36 (0.77, 2.40) 3 55.2% (0.107) 1.60 (1.06, 2.42) 3 0.0% (0.715)
≥2 prevalent HPV types (vs. HPV-negative) 2.30 (1.79, 2.95) 3 0.0% (0.497) 2.12 (1.21, 3.71) 2 11.3% (0.288)
Increase in HIV risk with no. of HPV types 1.30 (1.19, 1.42) 2 0.0% (0.331) 1.22 (1.07, 1.39) 2 0.0% (0.344)
Increase in HIV risk with no. of HR-HPV typesb c 1.59 (1.22, 2.09) 2 0.0% (0.758)
b. Additional exposures
Prevalent HR-HPV (vs. HR-HPV-negative)a,b 2.26 (1.39, 3.68) 5 68.4% (0.013) c
Prevalent LR-HPV (vs. LR-HPV-negative)a 1.81 (1.44, 2.27) 4 0.0% (0.752) c
Prevalent HPV-16 or HPV-18 (vs. HPV-16 and
HPV-18 negative)a
1.84 (1.25, 2.69) 2 0.0% (0.554) 1.20 (0.74, 1.94) 3 16.9% (0.300)
Prevalent HPV-6, HPV-11, HPV-16 or HPV-18 (vs. HPV-6,
HPV-11, HPV-16 and HPV-18 negative)a
1.62 (1.11, 2.36) 2 0.0% (0.964) 1.34 (0.88, 2.04) 3 14.3% (0.311)
Prevalent HPV-6, HPV-11, HPV-16, HPV-18, HPV-31,
HPV-33, HPV-45, HPV-52 or HPV-58 (vs. HPV-6,
HPV-11, HPV-16, HPV-18, HPV-31, HPV-33,
HPV-45, HPV-52 and HPV-58 negative)a
c 1.92 (1.06, 3.49) 2 52.4% (0.147)
aOther types are possible.
bIncludes Auvert (2010) which had a high possibility of reverse causality.
cIndicates pooling not possible due to N < 2.
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cannot totally be excluded, especially by partner and/or part-
nership characteristics (influencing the likelihood of exposure
to HPV and HIV) or previous HPV infections (which may pro-
tect or predispose to HPV infection) [71].
Conversely, mathematical modelling to assess potential biases
in STI and HIV interaction estimates for different study designs
has suggested that whilst statistical adjustment can help reduce
overestimation due to confounding, the magnitude of associa-
tion could also be underestimated in the presence of misclassifi-
cation of exposure [78,79]. Although we only included
longitudinal studies, which established the sequence of events
for HPV and HIV infections, there is still some potential for mis-
classification bias of both HIV and HPV exposure status. This is
more likely to be an issue for HPV as the exposure (review 2),
since HPV infection is a common infection with a finite duration
(in contrast to HIV). However, most studies in review 2
assessed HPV status both at baseline and during follow-up. Fur-
thermore, over half of the studies in both reviews carried out
STI and HIV testing at least every 6 months. In any case, mis-
classification bias is generally expected to bias RR estimates
toward the null value, underestimating the magnitude of associ-
ation, which would not invalidate our conclusions. Indeed, an
early modelling study also showed that, even in the presence of
biological interactions, estimates of the role of STI on HIV acqui-
sition can also be substantially under-estimated, mainly due to
imprecise measurement of STI exposure resulting from less fre-
quent STI testing (especially >6 months) and longer window
periods of HIV testing (especially >6 weeks) [79] (Guibord P,
MSc Thesis).
Some studies reported multiple estimates of association for
different HPV exposures (review 2) and outcomes (review 1)
(i.e. HR-HPV, LR-HPV, [any] HPV), which also provide a form
of validation of consistency of results within a study, but may
however increase the likelihood of finding spurious associa-
tions. We also differentiated between “first HPV”, defined as
the acquisition of HPV DNA in those individuals without any
HPV-DNA present at baseline but who may have been
exposed to HPV in the past (i.e. not na€ıve), and “new HPV”,
defined as the acquisition of DNA of a new and different HPV
type in those individuals who already had HPV DNA present
at baseline. We also differentiated between clearance of “all”
and “any” HPV. Definition of a clearance event itself (i.e. on
the basis of only one, or successive negative tests) also varied
between studies. However, we did not find evidence that
these differences influenced our results.
The studies in review 2 were concentrated in Sub-Saharan
Africa, which may limit the generalizability of our results to
other settings. There were fewer study estimates for single
HPV vaccine types and LR-HPV associations (both reviews),
HPV incidence and clearance by CD4 count level (review 1)
and HIV acquisition by incidence and clearance of HPV
(review 2). This could partly be due to publication bias, of
which we found greater evidence for review 2 than review 1.
This was observed in funnel plots, in subgroup analysis com-
paring reported estimates that were slightly higher that esti-
mates that we calculated ourselves, and in our qualitative
assessment of selective reporting of statistically significant
associations. Nevertheless, we were able to successfully derive
several new RR study estimates from available data (where
the estimates themselves were not reported), which improved
the precision of crude pooled estimates and reduced
publication biases. It also meant that we were not able to
derive adjusted estimates controlling for potential con-
founders, and as a proportion of studies fewer adjusted esti-
mates were available for review 1 than 2. Heterogeneity
(based on the I2 statistic), was particularly high across esti-
mates of HIV on HPV clearance, but results from subgroup
analyses showed that pooled effect sizes remained similar
across the subgroups examined.
In our review we have comprehensively summarized all the
available observational evidence on HIV and HPV interactions.
Our review was designed to minimize and assess the possibil-
ity of confounding and bias affecting our findings. We
restricted our analysis to longitudinal studies of the associa-
tions, and carried out extensive sensitivity analyses, comparing
adjusted and unadjusted estimates in multiple ways, extracting
information on the comparability of exposed and unexposed
groups, and exploring the influence of possible selective
reporting of non-significant results. The likelihood of confound-
ing explaining the associations in not the only consideration
when assessing the plausibility for causation. For example, our
results meet many of the 9 Bradford Hill criteria for causality
[80], which strengthens the case for the existence of biological
interactions between HIV and HPV. The strength of the associ-
ations was consistent across HPV types and study and popula-
tion characteristics. Longitudinal studies maximize the
likelihood of the exposure preceding the outcome, that is, min-
imize the risk of reverse causation (timing). We found some
evidence of a dose–response (HPV acquisition by CD4 cell
count compared to HIV-negative individuals, and effect of
number of HPV types on HIV acquisition). Additional evidence
of a biological dose–response also comes from studies com-
paring HPV acquisition and clearance by CD4 levels among
PLHIV only, which was not the purpose of our study
[72,81,82]. The associations found are also biologically plausible
[83]. HIV may increase susceptibility to HPV infection and
persistence of HPV infection among PLHIV due to immunode-
ficiency, the inflammatory response to HIV infection, immune
dysregulation at the site of HIV infection, and/or the effects
of HIV on HPV transcription and translation [73,84,85]. A
recent meta-analysis suggested that women living with HIV
(WLHIV) on ART had lower HR-HPV prevalence than those
not on ART after adjusting for CD4 cell count and ART dura-
tion, suggesting that ART may repair some of the damages
induced by HIV immunodeficiency [11]. HPV may in turn
directly facilitate HIV acquisition by increasing or altering the
density of HIV target cells (such as T lymphocytes and
Langerhans cells) and weakening the physical epithelial barrier
to HIV [86]. Whilst we found that the magnitude of the asso-
ciation was similar by timing of HPV infection (incident, preva-
lent or cleared infection), differing types and density of
immunological cells in the genital area could in theory trans-
late into varying risk of HIV acquisition over the course of
HPV infection and warrants further investigation. A recent
systematic review and meta-analysis of 57 studies found
higher risk of HIV acquisition in those with incident HSV-2
infection (compared to those without HSV-2 infection) than
was found for prevalent HSV-2 infection [75]. The interactions
between HIV and HPV could be analogous to the interactions
between HIV and HSV-2 in terms of some similarity of biolog-
ical mechanisms. In future, better evidence of these interac-
tions could be obtained from discordant couple studies and/or
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studies with more frequent STI and HIV testing, using the
best HIV tests with the shortest window period, and by ade-
quately measuring potential sexual risk factors among partici-
pants and their partners [71].
4 | CONCLUSIONS
Our study provides an evidence base for multiple biological
interactions between HIV and HPV. These interactions have a
number of important clinical, epidemiological and public health
implications. In particular, the excess burden of HPV in PLHIV
has implications for the clinical management of PLHIV requir-
ing more frequent screening, follow-up and management of
precancerous lesions due to HPV. HPV vaccination, which has
been proven to be safe and immunogenic among PLHIV, may
confer particular benefit to this group [87], and help to con-
trol HPV infections and related cancer more efficiently at pop-
ulation-level [7]. Recent modelling studies suggest that as
PLHIV are disproportionately infected with HPV they are
more likely to transmit it making them an important group for
focused HPV prevention [88]. Increasing HPV vaccination cov-
erage in low- and middle-income countries, in particular
among PLHIV, is an aim of the Pink Ribbon Red Ribbon
(PRRR) initiative, launched by the George W. Bush Institute,
the United States Government through the U.S. President’s
Emergency Plan for AIDS Relief (PEPFAR), and the Joint Uni-
ted Nations Programme on HIV/AIDS (UNAIDS) [89-91].
In addition, interventions such as HPV vaccination could in
theory have additional indirect benefits on HIV/AIDS, even if
the relative risk of HIV acquisition due to HPV is modest.
Given the burden of HPV and HIV and abundance of co-infec-
tions, HPV vaccination could prevent a non-negligible number
of AIDS deaths particularly in Sub-Saharan Africa. If reducing
HPV provides benefits for HIV, this would optimize HPV pro-
grammes, particularly in the context of combination preven-
tion, providing additional incentives for programme
implementation. Our comprehensive review can help inform
decisions on HPV vaccination in women and men, including
MSM. Mathematical modelling studies are needed to under-
stand the potential impact of these multiple interactions on
HIV and HPV trends and in the context of intervention rollout
for high HIV prevalence settings.
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Appendix S1. Additional supporting information.
Figure S1. Forest plots of the crude relative risk (RR) by HIV
status of: (S1a) incident LR-HPV infection; (S1b) incident HPV-
6/HPV-11 infection; (S1c) clearance of LR-HPV.
Figure S2. Forest plots of the crude and adjusted relative risk
(RR) by HIV status of: (S2a) incident HPV-16/HPV-18 infec-
tion by CD4 cell count; (S2b) clearance of HPV-16/HPV-18/
HPV-31/HPV-45 by CD4 cell count.
Figure S3. Funnel plot of the crude estimates for HIV on inci-
dent HPV.
Figure S4. Funnel plot of the crude estimates for HIV on inci-
dent HR-HPV.
Figure S5. Funnel plot of the crude estimates for HIV on
clearance of HPV.
Figure S6. Funnel plot of the crude estimates for HIV on
clearance of HR-HPV.
Figure S7. Funnel plot of the crude estimates for prevalent
HPV on HIV.
Figure S8. Funnel plot of the crude estimates for prevalent
HR-HPV on HIV.
Table S1. Summary of the 41 publications identified reporting
on the effect of HIV infection on HPV acquisition and clear-
ance (review 1).
Looker KJ et al. Journal of the International AIDS Society 2018, 21:e25110
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25110/full | https://doi.org/10.1002/jia2.25110
21
Table S2. Summary of the 15 publications identified reporting
on the effect of HPV infection or clearance on HIV acquisition
(review 2).
Table S3. Additional study characteristics used to assess qual-
ity of studies from publications included in the review of longi-
tudinal studies of the effect of HIV on HPV acquisition and
clearance (review 1).
Table S4. Additional study characteristics used to assess qual-
ity of studies from publications included in the review of longi-
tudinal studies of the effect of HPV infection and clearance on
HIV (review 2).
Table S5. Subgroup analyses of the association between prior
exposure to HPV and subsequent HIV infection by participant
and study characteristics (review 2).
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